Tevogen Inc. Operating Cash Flow
Tevogen Inc. (TVGN) reported Operating Cash Flow of -$5.74 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-14
- Tevogen Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$3.01M.
- Tevogen Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$2.73M.
- Tevogen Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$2.18M.
- Tevogen Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$3.65M.
- Tevogen Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$12.33M.
- Tevogen Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$12.00M.
- Tevogen Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$8.17M.
- Tevogen Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$215.40K.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 3 month as first filed | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 6 month as first filed | Net Cash Provided by (Used in) Operating Activities 8 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 9 month as first filed | Net Cash Provided by (Used in) Operating Activities 12 month | Net Cash Provided by (Used in) Operating Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$3.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$5.74M 10-Q · filed 2026-08-14 | -$7.92M derived: sum of 3 quarters · filed 2026-08-14 | -$11.57M derived: sum of 4 quarters · filed 2026-08-14 | |||||
| 2026-03-31 | -$2.73M 10-Q · filed 2026-05-15 | -$4.92M derived: sum of 2 quarters · filed 2026-05-15 | -$8.56M derived: sum of 3 quarters · filed 2026-05-15 | -$11.75M derived: sum of 4 quarters · filed 2026-08-14 | |||||
| 2025-12-31 | -$2.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$5.83M derived: sum of 2 quarters · filed 2026-03-31 | -$9.02M derived: sum of 3 quarters · filed 2026-08-14 | -$12.33M 10-K · filed 2026-03-31 | |||||
| 2025-09-30 | -$3.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$6.84M derived: sum of 2 quarters · filed 2026-08-14 | -$10.15M 10-Q · filed 2025-11-14 | -$13.19M derived: sum of 4 quarters · filed 2026-08-14 | |||||
| 2025-06-30 | -$3.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$6.50M 10-Q · filed 2026-08-14 | -$9.55M derived: sum of 3 quarters · filed 2026-08-14 | -$13.35M derived: sum of 4 quarters · filed 2026-08-14 | |||||
| 2025-03-31 | -$3.31M 10-Q · filed 2026-05-15 | -$6.36M derived: sum of 2 quarters · filed 2026-05-15 | -$10.16M derived: sum of 3 quarters · filed 2026-05-15 | -$13.14M derived: sum of 4 quarters · filed 2026-05-15 | |||||
| 2024-12-31 | -$3.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$6.85M derived: sum of 2 quarters · filed 2026-03-31 | -$9.83M derived: sum of 3 quarters · filed 2026-03-31 | -$12.00M 10-K · filed 2026-03-31 | |||||
| 2024-09-30 | -$3.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$6.79M derived: sum of 2 quarters · filed 2025-11-14 | -$8.95M 10-Q · filed 2025-11-14 | -$10.93M derived: sum of 4 quarters · filed 2025-11-14 | |||||
| 2024-06-30 | -$2.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$5.15M 10-Q · filed 2025-08-14 | -$7.12M derived: sum of 3 quarters · filed 2025-08-14 | -$8.92M derived: sum of 4 quarters · filed 2025-08-14 | |||||
| 2024-03-31 | -$2.16M 10-Q · filed 2025-05-14 | -$4.14M derived: sum of 2 quarters · filed 2025-05-14 | -$5.94M derived: sum of 3 quarters · filed 2025-05-14 | -$8.16M derived: sum of 4 quarters · filed 2025-05-14 | |||||
| 2023-12-31 | -$1.98M derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-02 | -$3.78M derived: sum of 2 quarters · filed 2025-04-02 | -$5.99M derived: sum of 3 quarters · filed 2025-04-02 | -$8.17M 10-K · filed 2025-04-02 | -$1.38M 10-K · filed 2024-04-29 | ||||
| 2023-09-30 | -$1.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-19 | -$4.02M derived: sum of 2 quarters · filed 2024-11-19 | -$6.19M 10-Q · filed 2024-11-19 | -$682.64K 10-Q · filed 2023-11-13 | -$6.21M derived: sum of 4 quarters · filed 2024-11-19 | ||||
| 2023-06-30 | -$2.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$4.39M 10-Q · filed 2024-08-14 | -$474.18K 10-Q · filed 2023-08-21 | -$4.41M derived: sum of 3 quarters · filed 2024-08-14 | -$4.45M derived: sum of 4 quarters · filed 2024-08-14 | ||||
| 2023-03-31 | -$2.18M 10-Q · filed 2024-05-28 | -$76.90K 10-Q · filed 2023-05-22 | -$2.19M derived: sum of 2 quarters · filed 2024-05-28 | -$2.23M derived: sum of 3 quarters · filed 2024-05-28 | -$2.28M derived: sum of 4 quarters · filed 2024-05-28 | ||||
| 2022-12-31 | -$13.86K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-29 | -$56.46K derived: sum of 2 quarters · filed 2024-04-29 | -$102.36K derived: sum of 3 quarters · filed 2024-04-29 | -$215.40K 10-K · filed 2024-04-29 | |||||
| 2022-09-30 | -$42.60K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$88.50K derived: sum of 2 quarters · filed 2023-11-13 | -$201.53K 10-Q · filed 2023-11-13 | ||||||
| 2022-06-30 | -$45.90K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-21 | -$158.94K 10-Q · filed 2023-08-21 | |||||||
| 2022-03-31 | -$113.03K 10-Q · filed 2023-05-22 | ||||||||
| 2021-12-31 | -$713.83K 10-K · filed 2023-04-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B |